These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36654091)

  • 21. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    Nordberg Backelin C; Fu M; Ljungman C
    ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity.
    Kim BS; Park IH; Lee AH; Kim HJ; Lim YH; Shin JH
    Arch Toxicol; 2022 Apr; 96(4):1065-1074. PubMed ID: 35152301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
    Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
    J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
    Huang HT; Huang JL; Lin PL; Lee YH; Hsu CY; Chung FP; Liao CT; Chiou WR; Lin WY; Liang HW; Chang HY
    ESC Heart Fail; 2022 Dec; 9(6):3825-3835. PubMed ID: 35945811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.
    Dillon EM; Wei SD; Gupta DK; Nian H; Rodibaugh BS; Bachmann KN; Naftilan AJ; Stevenson LW; Brown NJ
    J Card Fail; 2021 Nov; 27(11):1231-1239. PubMed ID: 34133968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of B-type natriuretic peptide and N-terminal pro-brain natriuretic peptide during acute decompensated heart failure in a chronic heart failure patient with reduced ejection fraction treated with Sacubitril/Valsartan: a case report.
    Tiepolo A; Nougué H; Damoisel C; Launay JM; Vodovar N; Mebazaa A
    Eur Heart J Case Rep; 2019 Sep; 3(3):ytz108. PubMed ID: 31660484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.
    Zhang W; Liu J; Fu Y; Ji H; Fang Z; Zhou W; Fan H; Zhang Y; Liao Y; Yang T; Wang X; Yuan W; Chen X; Dong YF
    Front Pharmacol; 2020; 11():600953. PubMed ID: 33519461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
    Li X; Zuo C; Chen C; Tian D; Li J; Fan L; Li X; Lv Q
    Int J Cardiol; 2023 Jan; 371():244-251. PubMed ID: 36174825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of valsartan against doxorubicin-induced cardiotoxicity: Histopathology and metabolomics in vivo study.
    Alhazzani K; Alotaibi MR; Alotaibi FN; Aljerian K; As Sobeai HM; Alhoshani AR; Alanazi AZ; Alanazi WA; Alswayyed M
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22842. PubMed ID: 34273911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
    Wu M; Guo Y; Wu Y; Xu K; Lin L
    Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
    [No Abstract]   [Full Text] [Related]  

  • 35. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
    Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM
    J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients.
    Yang L; Zhang M; Hao Z; Wang N; Zhang M
    ESC Heart Fail; 2022 Aug; 9(4):2428-2434. PubMed ID: 35437929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
    Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sacubitril/valsartan attenuates left ventricular remodeling and improve cardiac function by upregulating apelin/APJ pathway in rats with heart failure].
    Liu HZ; Gao CY; Yuan F; Xu Y; Tian H; Wang SQ; Zhang PF; Shi YN; Wei JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):690-697. PubMed ID: 35856226
    [No Abstract]   [Full Text] [Related]  

  • 40. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.